Lifeway Foods (NASDAQ:LWAY) reported a surge in first-quarter revenue that far outpaced analyst estimates, extending a multi-year growth streak fueled by the mainstreaming of gut-health products.
DarioHealth (NASDAQ:DRIO) posted first-quarter revenue of $5.6 million, a 6.7% increase from the fourth quarter of 2025.
Arbutus Biopharma (NASDAQ:ABUS), a clinical-stage biopharmaceutical company focused on infectious diseases, reported its financial results for the first quarter ended March 31, 2026.
BrainsWay (NASDAQ:BWAY) delivered a powerful first-quarter 2026 performance, marked by a 35% year-over-year revenue increase to $15.5 million.
Dyne Therapeutics (NASDAQ:DYN) ended the first quarter of 2026 with $972.2 million in cash, cash equivalents, and marketable securities.
Warby Parker (NYSE:WRBY) reported first-quarter results for 2026 that exceeded internal guidance across all key financial metrics, signaling resilient demand for its affordable luxury eyewear and integrated vision services.
IDEXX Laboratories (NASDAQ:IDXX) increased its financial projections for 2026 following a first quarter marked by robust demand for pet healthcare services and significant margin expansion within its core diagnostic segments.
BrightSpring Health Services (NASDAQ:BTSG) reported a landmark first quarter for 2026, delivering substantial growth across all key financial metrics.
Kodiak Sciences (NASDAQ:KOD) is set to present a series of clinical and preclinical advances at the American Uveitis Society (AUS) and the Association for Research in Vision and Ophthalmology (ARVO) annual meetings between May 2 and May 7, 2026.
Pentair (NYSE:PNR) reported a strong start to the 2026 fiscal year, characterized by steady sales growth and a significant expansion in operating efficiency.
